Nanostics in the Media
Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
- Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
- The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform.
- The study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Cancer Research at the University of Alberta.
Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies.
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution. ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer. Nanostics is excited to work with this Partner to reach the recruitment numbers and diversity goals of the clinical study.
Nanostics featured on Alberta Impact Episode 5 with Bryce Lambert
1 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare decisions. Their core technology is in development to be able to diagnose prostate cancer from a simple blood test.
Webinars / Technical Notes

Liquid biopsy EV analysis with small particle flow cytometry
Small particle flow cytometry using 3 light scatter detectors enhances extracellular vesicle analysis in liquid biopsies, highlighting the potential to segregate EVs by refractive index
Pink, Desmond, Basu, Arghya, Valencia, Juliana, Pham, Diana, and Lewis, J.D.
Click here for CYTO 2022 POSTER PRESENTATION
Click here for CYTO 2022 SLIDE PRESENTATION
Extracellular vesicle analysis using “small particle” flow cytometry would be greatly enhanced if data from materials of different refractive index (RI) could be segregated. Likewise, relative sizing of EVs using small particle flow cytometry is confounded by the influence of RI on light scatter. Beads of different composition and refractive index scatter light differently, so that small beads of high RI and large beads of lower RI can have overlapping signals on a two dimension light scatter plot. As particle size decreases, light scatter intensity profiles eventually merge regardless of refractive index. In this project, we aimed to demonstrate graphically, (1) the enhancement of EV flow analysis when using an additional angle of light scatter collection (medium angle of light scatter, MALS) to identify different sample components (e.g. lipids, protein, extracellular vesicles) and (2) the practical reality of sample component overlap at different particle sizes.
Nanostics CSO Desmond Pink will be presenting this work at CYTO 2022, June 3-7, in Philadelphia, US.
CYTO 2022 MOVING FORWARD
Empowering Scientists. Advancing Cytometry.
Antibody titration for flow cytometric analysis of Extracellular Vesicles: Are cell based protocols up to the task?
Date: 06/10/2021
Time: 10:00 am
Venue: Watch on Demand Now by clicking on the Address Button
Desmond Pink, CSO Nanostics
Why is ANTIBODY TITRATION critical to the success of any flow cytometry experiment?
In this webinar, Desmond Pink will investigate and report on antibody titration considerations for EVs, including sample concentration and processing, conjugate decisions, event triggering, platform differences, data processing and analysis, and real-world examples that highlight when antibody titration is necessary.
White Paper: Performance Qualification for MicroFlow Cytometers: Understanding technical limitations to improve your research
As microflow cytometry matures toward clinical applications for extracellular vesicle (EV) analysis, a concerted effort to improve reproducibility has begun. The new MISEV and MISEV MISEV-Flow guidelines are critical to enabling this reproducibility.
AUTHOR: DESMOND PINK, MICHAEL WONG, DIANA PHAM, RENJITH PILLAI, LEANNE STIFANYK, SYLVIA KOCH, REBECCA HIEBERT, OLIVER KENYON, AND JOHN LEWIS
Achievements

Be where the future is. Be at INVENTURES 2022
Inventures June 1-3
What: Nanostics is one of 5 finalist startups and CCO Colin Coros will be pitching for our team at the Game-changing Health Pitch Session.
When: June 2, 11:15 am-12pm
Where: Calgary Convention Centre, Hall E. Calgary, Alberta, Canada
UPDATE: Wow! The Inventures 2022 Startup Gamechanging Health Pitch Winner is…Nanostics with CCO Colin Coros pitching! Thank you #Inventures2022 for an excellent pitch session with a super lineup of Startups and awesome conference – it was great to see everyone in-person!
BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2018 Awards Gala
CALGARY, Alberta — At its 2018 awards gala, BioAlberta, the province’s life sciences industry association, recognized two leaders for their innovation and achievements. BioAlberta congratulates Circle Cardiovascular Imaging Inc. for winning its Company of the Year award and Dr. John Lewis for winning its Scientific Achievement and Innovation Award.
FALLING WALLS
Dr. John Lewis is the winner of the University of Alberta-TEC Edmonton Falling Walls Venture Competition which earned him entrance to the Falling Walls Finale Competition (the International Conference on Future Breakthroughs in Science and Society) which will be held in Berlin this November. Some travel expenses will be paid for.